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Available online 14 September 2007A large body of evidence indicates that the hormone erythropoietin (EPO) exerts beneficial
effects in the central nervous system (CNS). To date, EPO's effect has been assessed in several
experimental models of brain and spinal cord injury. This study was conducted to validate
whether treatment with recombinant human EPO (rHuEPO) would limit the extent of injury
following experimental TBI. Experimental TBI was induced in rats by a cryogenic injury
model. rHuEPO or placebo was injected intraperitoneally immediately after the injury and
then every 8 h until 2 or 14 days. Forty-eight hours after injury brain water content, an
indicator of brain edema, was measured with the wet–dry method and blood–brain barrier
(BBB) breakdownwas evaluated by assay of Evans blue extravasation. Furthermore, extent of
cerebral damagewas assessed. Administration of rHuEPOmarkedly improved recovery from
motor dysfunction compared with placebo group (P<0.05). Brain edema was significantly
reduced in the cortex of the EPO-treated group relative to that in the placebo-treated group
(80.6±0.3% versus 91.8%±0.8% respectively, P<0.05). BBB breakdown was significantly lower
in EPO-treated group than in the placebo-treated group (66.2±18.7 μg/g versus 181.3±21 μg/g,
respectively, P<0.05). EPO treatment reduced injury volume significantly compared with
placebo group (17.4±5.4 mm3 versus 37.1±5.3 mm3, P<0.05). EPO, administered in its
recombinant form, affords significant neuroprotection in experimental TBI model and may
hold promise for future clinical applications.
© 2007 Elsevier B.V. All rights reserved.Keywords:
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Traumatic brain injury1. Introduction
Traumatic brain injury (TBI) is a major cause of morbidity and
mortality in the United States. It is estimated that each year,
on average, TBIs associated with 1.1 million emergency de-
partment visits, 235,000 hospitalizations, and 50,000 deathsPoliclinico P. Giaccone, V
so).
er B.V. All rights reserved(2007). Despite improvements in medical interventions, there
are still currently no neuroprotective agents available to coun-
teract secondary or delayed damage to the traumatically in-
jured human brain or to promote its repair. Many researches
have long explored agents with proved in vitro and in vivo
neuroprotective effect in order to assist in repairing damagedia del Vespro 127, 90100, Palermo, Italy. Fax: +39 0916553227.
.
Fig. 2 – Graph showing the effect of rHuEPO administration
on tissue water content, an indicator of brain edema
after TBI. By 48 h after TBI, the injured cortex showed
significant brain edema, which was notably reduced in the
ipsilateral cortex after treatment with rHuEPO as compared
with placebo. Data are presented as mean±standard
deviation; IC, ipsilateral cortex; CC, contralateral cortex;
*, P<0.05, as compared with contralateral cortex; **, P<0.05,
as compared with placebo treatment.
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monstrated to be neuroprotective in preclinical models, only a
part of these have entered clinical development and some of
those that survived early safety trials have been studied in
controlled efficacy trials. Despite these efforts, all phase III
trials have so far failed in demonstrating efficacy of neuro-
protective agents.
Progress in the development and synthesis of new drugs
represents the first step in tailoring a potential successful
neuroprotective agents. In this scenario, a large body of evi-
dence has pointed out the efficacy of the hormone erythro-
poietin (EPO) as neuroprotectant. Although peripherally
administered recombinant human EPO (rHuEPO) has shown
to penetrate the blood–brain barrier (BBB) and reduce brain
injury following a variety of insults (Brines et al., 2000; Digi-
caylioglu and Lipton, 2001; Grasso et al., 2004), its potential
neuroprotective efficacy in an in vivo model of experimental
TBI has been scarcely investigated (Brines et al., 2000; Lu et al.,
2005; Ozturk et al., 2005; Shein et al., 2005; Siren et al., 2006;
Verdonck et al., 2007; Yatsiv et al., 2005). Evidence shows
widespread efficacy of rHuEPO in injury models of spinal cord
(Celik et al., 2002; Gorio et al., 2002; Grasso et al., 2006), sub-
arachnoid hemorrhage (Buemi et al., 2002a,b; Catania et al.,
2002; Grasso, 2001; Grasso et al., 2002a,b; Springborg et al.,
2002), retina, and the heart damage (Calvillo et al., 2003; Junk
et al., 2002).Fig. 1 – The effect of rHuEPO treatment on cognitive behavior
and swim speed in a Morris water maze after TBI.
(a) Sham-injured control animals demonstrated an ability to
learn a cognitive task as demonstrated by a reduced latency
to find the platform over time, whereas placebo-treated
injured animals showed a significantly impaired ability to
complete this task compared to shams (P<0.05). rHuEPO
treatment significantly reversed this impairment in injured
animals (* P<0.05). (b) Mean swim speeds generated from all
trials in the experiment. While there was an overall
significant effect of treatment, no significance was found
between any of the treatment groups.The mechanisms by which EPO exerts its beneficial effects
are incompletely understood. Available evidence suggests
that EPO acts in a coordinated fashion at multiple levels to
limit the production of tissue-injuring molecules such as glu-
tamate (Kawakami et al., 2001), reverse vasospasm (Grasso,
2001), attenuate apoptosis (Celik et al., 2002; Digicaylioglu and
Lipton, 2001), modulate inflammation (Brines et al., 2000), and
recruit stem cells (Shingo et al., 2001). Furthermore, a recent
phase II clinical trial has demonstrated significant improve-
ment in outcome of ischemic stroke patients administered
rHuEPO intravenously within 8 h of the onset of symptoms
(Ehrenreich et al., 2002).
These data support the role of EPO as an essential mediator
of protection in the CNS. Based on this evidence we designed
the present study to investigate further the role of EPO fol-
lowing experimental TBI. Specific purpose of this researchwasFig. 3 – Graph showing the effect of rHuEPO on Evans blue
extravasation, an indicator of BBB permeability, after TBI. By
48 h after TBI, the injured cortex showed significant BBB
permeability, which was notably reduced after treatment
with rHuEPO. Data are presented as mean±standard
deviation; IC, ipsilateral cortex; CC, contralateral cortex;
*, P<0.05, as comparedwith sham-operated rats; **, P<0.05 as
compared with placebo treatment.
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rological impairment, brain edema formation, blood–brain
barrier (BBB) breakdown, and injury volume extent after TBI.
Brain injury was induced by a cryogenic injury model, a para-
digmwell known to produce brain lesions resembling some of
the aspects of TBI in patients (Amorini et al., 2003; Fukui et al.,
2003; Zhao et al., 2003).2. Results
2.1. Neurological findings
Cerebral injury induced significant neurological deficits in
placebo-treated subjects when compared to sham animals
(P<0.05). rHuEPO administration reduced the deficit observed
in placebo-treated animals by significantly shortening the
latency required to complete the task over time (P<0.05). In
addition, animals given rHuEPO did not present significantly
different latencies from sham-injured animals. There was an
overall significant effect of treatment on the mean swim
speeds displayed throughout the behavioral experiment of the
subjects (P<0.05) (Fig. 1).
2.2. Brain water content quantification
Overall, TBI caused a significant increase in the percentage of
water content in the injured ipsilateral cortex compared with
the contralateral cortex (92.3±0.4% 71.1±0.3%, respectively,
P<0.05). Treatment with rHuEPO reduced the percentage of
water content in the ipsilateral cortex compared with the
contralateral cortex (80.6±0.3% and 71.1±0.3%, respectively,
P<0.05) and compared with placebo-treated group (80.6±0.3%
versus 91.8%±0.8%, n=6, P<0.05) (Fig. 2).
2.3. BBB permeability assessment
In both treatment groups Evans blue extravasation in the
ipsilateral cortex was significantly higher than that of the
contralateral cortex. However, rHuEPO treatment reduced dye
extravasation in the ipsilateral cortex for about 60% as com-
pared with placebo treatment (66.2±18.7 μg/g versus 181.3±
21 μg/g, respectively, n=6 for both groups, P<0.05) (Fig. 3).Fig. 4 – Graph showing the lesion volume assessed 48 h after
TBI. Placebo-treated rats had larger lesion volumes than
rHuEPO-treated rats, as measured by TTC staining (* P<0.05).
Data are expressed as mean±standard deviation.2.4. Lesion volume quantification
TBI produced a region of necrotic tissue in the right parietal
cortex. Treatment with rHuEPO significantly reduced injury
volume by 53% as compared with placebo treatment (from
37.1±5.3 mm3 in placebo-treated animals to 17.4±5.4 mm3 in
rHuEPO-treated animals, n=6 for both groups, P<0.05) (Fig. 4).3. Discussion
The present study demonstrates that rHuEPO confers neuro-
protection in an in vivo model of TBI and emphasizes its
beneficial effect on neurological dysfunction, brain edema
formation, BBB dysfunction, and cerebral tissue injury extent
following a cryogenic model of brain damage. Such a model
mimics several pathophysiological characteristics of human
focal cortical contusion (Nag, 1996) and produces a reproduc-
ible, demarcated lesion to the neocortex that allows evalua-
tion of the efficacy of compounds with a neuroprotective
potential (Hortobagyi et al., 2000).
The present findings extend previouswork by showing that
rHuEPO significantly reduces brain injury and improves neu-
rological recovery following traumatic insults (Brines et al.,
2000; Lu et al., 2005; Ozturk et al., 2005; Shein et al., 2005; Siren
et al., 2006; Verdonck et al., 2007; Yatsiv et al., 2005). In parti-
cular, rHuEPO administration improved both functional and
cognitive recovery of the rats with an effect that was signi-
ficantly shown since the early stage after TBI and lasted for 15
days. Beside an improved neurobehavioral recovery, rHuEPO-
treated rats presented with less brain edema than placebo-
treated group, as demonstrated by the water content assess-
ment, with a better BBB integrity and a reduced cerebral injury
volume as compared with placebo treatment group.
Although the role of EPO as a neuroprotectant has been
studied extensively in a wide range of in vitro and in vivo
models of brain injury, up to date, there are only few studies
evaluating the effect of rHuEPO after experimental TBI (Brines
et al., 2000; Lu et al., 2005; Ozturk et al., 2005; Shein et al., 2005;
Siren et al., 2006; Verdonck et al., 2007; Yatsiv et al., 2005) and
none has used a cryogenic injury paradigm. Neurobehavioral
improvement after EPO administration has been reported in
other studies where different models of brain injury were
used. In this regard, it has been demonstrated that rat pups
given rHuEPO had a significantly better performance in the
Morris water maze test compared with untreated animals
(Kumral et al., 2004). Others subjected rats to bilateral tran-
section of the fimbria-fornix and rHuEPO treatment allowed a
better posttraumatic functional recovery (Mogensen et al.,
2004). We have previously demonstrated that rHuEPO pre-
vented cognition impairment in a gerbil transient brain ische-
mia model (Catania et al., 2002) and neurological dysfunction
following experimental subarachnoid hemorrhage in rabbits
(Grasso et al., 2002a). These studies and the present findings
suggest that the neuroprotective effects exerted by rHuEPO
administration in models of brain damage are associated with
the maintenance of neurological functions.
In the present study we have also demonstrated that EPO
can limit the BBB dysfunction after TBI. Our findings are in
agreement with previous studies where treatment with EPO
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seizure (Uzum et al., 2006) and to reduce infarct size after
ischemia/reperfusion (Liu et al., 2006). An in vitro study has
also shown that EPO protects against the VEGF-induced per-
meability of the BBB, decreases the levels of endothelial nitric
oxide synthase, and restores junction proteins (Martinez-
Estrada et al., 2003).
The modality by which rHuEPO acts in the CNS across the
BBB remains a matter of controversy. Expression of EPOR in
brain capillary endothelial cells and the ability of systemically
administered EPO to cross the BBB have been reported in vivo
(Brines et al., 2000; Grasso et al., 2002a). Furthermore, it has
been suggested that, after systemic administration, rHuEPO
may be transported across the BBB by a specific receptor-
mediated mechanism (Brines et al., 2000).
The basis of EPO-mediated neuroprotection depends upon
expression of a cognate receptor where the drug can be bound
at the time of exposure. EPO exerts its effects through the
activation of its receptor (EPOR), part of the cytokine-receptor
type I superfamily. Recent evidence suggests that the hema-
topoietic and tissue-protective activities could be separated
and that the hormonal and neuroprotective actions of EPO can
occur via different signaling systems (Leist et al., 2004). Spe-
cifically, the receptor complex mediating the neuroprotective
effects of EPO has been reported to be associated with the
common receptor (cR) subunit, also known as CD131, which is
the signal-transducing component used by the granulocyte-
macrophage colony stimulating factor (GM-CSF), IL-3, and IL-5
receptors (D'Andrea and Gonda, 2000).
Although the mechanisms by which EPO acts as neuropro-
tectant are still a matter of controversy, an increasing number
of evidence suggests that EPOR activation following EPO bind-
ing inhibits neuronal apoptosis (Celik et al., 2002; Digicaylioglu
and Lipton, 2001). Prevention of neuronal apoptosis involves
the activation of JAK-2 and nuclear factor (NF)-kB signaling
pathways (Digicaylioglu and Lipton, 2001). In addition, EPO
also appears to prevent apoptotic injury through an Akt de-
pendent mechanism (Bao et al., 1999).
EPO-mediated neuroprotection after TBI includes other
triggering events such as restoration andmaintenance of vas-
cular autoregulation and BBB integrity. In this regard, it is well
known that TBI is associated with an early loss of vascular
autoregulation leading to the development of vascular hyper-
permeability and tissue edema that ultimately cause neuronal
degeneration (Unterberg et al., 2004). In preclinical injury
models of cerebral vasospasm induced by subarachnoid he-
morrhage (Grasso et al., 2002a; Springborg et al., 2002) it has
been shown that EPO can reverse vascular spasm thus
providing neuroprotection. The mechanism of this vascular
effect of rHuEPO appears to depend on the modulation of
inducible nitric oxide synthase activity (Squadrito et al., 1999).
Because onemechanism explaining the neuroprotective effect
of rHuEPO has been shown to depend on inhibition of nitric
oxide production (Calapai et al., 2000), it is reasonable to hy-
pothesize that similar mechanisms may be relevant after TBI.
Furthermore, inflammatory cells are involved in the late dam-
age that occurs to the oligodendrocytes that provide brain
degeneration (Leinhase et al., 2006). rHuEPO appears to reduce
the inflammatory infiltrate and in this manner likely reduces
the contribution of late injury to the neurological deficit (Gorioet al., 2002). However, antiapoptotic action and reduced neuro-
inflammatory response by rHuEPO (Brines et al., 2000; Siren
et al., 2001; Yatsiv et al., 2005) are based on mechanisms
needing several hours, after the insult, to be effective. Pro-
cesses occurring in the early stage after TBI, such as release of
glutamate, lactate, potassium, calcium, free oxygen radicals,
histamine, and kinins by injured cells, seem to be more rele-
vant in the pathophysiological mechanisms underlying brain
damage following TBI (Unterberg et al., 2004). In this regard,
EPO administration has been associated with protection from
glutamate toxicity by activation of calcium channels (Saka-
naka et al., 1998), production of antioxidant enzymes in neu-
rons (Koshimura et al., 1999), and reduction of the NO toxicity
in neurons (Calapai et al., 2000; Sakanaka et al., 1998).
In conclusion, our results confirm the positive effects
exerted by rHuEPO in treating the post-TBI pathogenic cascade
because rHuEPO significantly reduced brain edema formation,
BBB dysfunction, and cerebral tissue injury following the
trauma, and consequently, the neurological outcome in this
experimental setting. The present findings extend the work of
previous studies in several ways. First, we have demonstrated
that systemic administration of rHuEPO can significantly
attenuate TBI related injuries in a well-characterized and rep-
roducible experimental model. Second, we have documented
that the neuroprotective effect of rHuEPO is evident even 48 h
later the induction of the trauma. Finally, we have observed an
improvement of the neurological outcome since the early
stage of the injury lasting for almost 2 weeks. Such an obser-
vation strongly supports further studies in order to assess
additional information about a possible clinical use of EPO
after the onset of TBI.4. Conclusions
In the present study conducted in rats, our results indicate
that EPO provides tissue protection after experimental TBI.
This finding, consistent with beneficial effect on neurological
dysfunction, brain edema formation, BBB dysfunction, and
cerebral tissue injury following a cryogenic injury model of
brain damage, has clear relevance for treatment of TBI.5. Experimental procedures
5.1. Animal preparation
Procedures involving animals and their care were conducted
in conformity with institutional guidelines that are in com-
pliance with Italian and international laws and policies.
Rats were anesthetized with isofluorane (2%) in oxygen
(0.8 l/min) and nitrous oxide (0.4 l/min). Cryogenic cerebral
injury was induced as previously described (Gorlach et al.,
1998). Briefly, a cryogenic lesion was produced by application
of a precooled copper cylinder (∅ 5 mm, −78 °C) on the dura
mater. Under surgical microscope the skull was exposed by a
midline incision and a circular hole (approximately 5 mm in
diameter) was drilled on the skull over the right temporo-
parietal cortex leaving the dura intact. The precooled cylinder
was lowered onto the dural surface and kept in place for 60 s.
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using the same technique, but without producing cryogenic
injury.
After the operation, rats were housed in pairs to reduce
isolation-induced stress. Animalsweremaintained in a 12-hour
light/dark cycle with water and food freely available at an
ambient temperature of 25 to 27 °C. No prophylactic antibiotics
were given.
5.2. Treatment groups and drug administration
Sixty-six male Sprague–Dawley rats, each weighing 250 to
350 g, were assigned to one of three groups: Group 1, sham
operated; Group 2, TBI plus placebo; or Group 3, TBI plus
rHuEPO; each group contained twenty-two animals.
All injections were administered 5 min after induction of
TBI and were continued every 8 h up to 14 days in animals
which underwent neurological examination (4 animals from
each groups), and 48 h in animals undergoing brain edema,
BBB integrity, and lesion volume quantification (6 animals
from each group). All doses of placebo or rHuEPOwere admin-
istered intraperitoneally. Rats in Group 2 received the vehicle
used to administer rHuEPO (serum albumin [2.5 mg/ml], so-
dium chloride [5.84 mg/ml], sodium citrate [5.8 mg/ml], anhy-
drous citric acid [0.057 mg/ml], and water), at a dose of 1 ml/kg
of body weight as placebo. Rats in Group 3 were given rHuEPO
at a dose of 1000 IU/kg. The dose of 1000 IU/kg was based on
results obtained in our previous studies (Grasso, 2001; Grasso
et al., 2002a,b).
5.3. Neurological function evaluation
To examine cognitive deficits, a Morris water maze paradigm
was used (Morris, 1984). Briefly, the task involved rat repeated-
ly locating within 90 s a clear platform submerged in one of
four locations in a fiberglass pool. If unsuccessful in a trial, the
subjects were gently guided to the platform. Once on the
platform, subjects were allowed to remain there for 30 s. Extra
visual cues were placed around the room and the platform
was kept in a fixed position for each rat. The experiment
extended for 14 consecutive days, beginning on day 1 after
injury, and consisted of two sessions per day (four trials per
session), with an inter-trial interval of 30 min and an inter-
session interval of 120 min. Each trial was recorded and
movement was tracked using a commercially available soft-
ware. The length of time taken to reach the platform and swim
speeds of the animals could then be calculated.
5.4. Brain edema assessment
Brain water content, an indicator of brain edema, was mea-
sured with the wet–dry method 48 h after injury (Dogan et al.,
1997; Gove et al., 1997). After the animals were killed by deca-
pitation under anesthesia, their brains were removed and the
ipsilateral and contralateral cortical tissues were dissected
and weighed immediately to assess wet weight. After drying
in a desiccating oven for 48 h at 70 °C, the tissues were re-
weighed to yield dry weight. The percentage of water in the
tissues was calculated according to the formula: %water=
100×(wet weight−dry weight)/wet weight.5.5. Evaluation of BBB integrity
The integrity of the BBB was investigated by assessing extra-
vasation of Evans blue dye as previously described (Iseki et al.,
1996). Briefly, Evans blue dye (2% in saline) was injected
intravenously (3 mg/kg) 48 h after TBI and allowed to circulate
60 min. To remove the intravascular dye, we perfused the
animals with saline through the left ventricle at 100 cm of
water pressure until clear perfusion fluid was obtained from
the right atrium. After the animals were decapitated, the
brains were removed and the ipsilateral and contralateral cor-
tical tissues were dissected. Each tissue sample was weighed,
homogenized in 2 ml of 50% trichloroacetic acid (w/v), and
centrifuged for 20min. The supernatant was then diluted with
solvent (one part 50% trichloroacetic acid to three parts
ethanol). Tissue levels of Evans blue dye were assessed using
a spectrofluorometer at an excitation wavelength of 620 nm
and an emission wavelength of 680 nm. Sample values were
compared with those of Evans blue dye standards mixed with
the solvent (100–1000 ng/ml).
5.6. Lesion volume quantification
Forty-eight hours after surgery, the rats were perfused with
10% paraformaldehyde under anesthesia and brains rapidly
removed and sliced into 1-mm slices in a rat brain matrix. To
quantify lesion volume, brain slices were incubated in 2%
2,3,5-triphenyltetrazolium chloride (TTC; Sigma, St Louis, MO,
USA) in 0.9% saline for 30min at room temperature in the dark
and stored at 4 °C in neutral 10% formalin for up to 7 days prior
to analysis. Digital images of each slice were taken using a
scanner, and lesion volume, defined as the area of unstained
tissue, calculated using ScionImage software (Frederick, MD,
USA).
5.7. Statistical analysis
Data were expressed as the mean±standard deviation and
were analyzed by using one-way analysis of variance (ANOVA)
followed by Dunett's post hoc multiple comparison test. A
P value of <0.05 was considered statistically significant.R E F E R E N C E S
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